Page 1 of 4



LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

SERIAL NO. 10/827,083	ATTORNEY DOCKET NO.			
	3352.2.1.4			
FILING DATE April 19, 2004	GROUP ART UNIT 1645			
APPLICANT:				
Yao Xiong Hu				

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE (MM-DD-YYYY)	NAME OF PATENTEE OR APPLICANT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR FIGURES APPEAR
AS	A1	4,777,239	11/11/1988	Schoolnik et al.	All
	A2	5,629,146	05/13/1997	Dillner et al.	All
	A3	5,629,161	05/13/1997	Muller et al.	All
	A4	5,753,233	05/19/1998	Bleul et al.	All
	A5	5,932,412	08/03/1999	Dillner et al.	All
	A6	6,096,869	08/01/1999	Stanley et al.	All
	A7	6,183,746	02/06/2001	Urban et al.	All

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE (MM-DD-YYYY)	NAME OF PATENTEE OR APPLICANT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR FIGURES APPEAR	т
A	A8	WO 87/01375	03/12/1987	Breitburd et al.	All	
	A9	EP 0344940	12/12/1989	Dillner et al.	All	
	A10	EP 0 594 613	11/28/1991	Dillner et al.	All	
	A11	WO 99/10744	03/04/1999	Medigene	All	

## **NON-PATENT DOCUMENTS**

EXAMINER INITIAL		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
As	A12	HAYWARD et al., Who gets screened for cervical and breast cancer?, Archives of Internal medicine, 148:1117-81, 1988.
B	A13	HU YX, Introduction and prospect of application of biogenetic engineering, Guangzhou Medical Journal, 2:8-10, 1990

EXAMINER	DATE CONSIDERED	4/25/05
----------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

	61	PE	· Ve	
	OCT	267	2004	15. 18.
(A)	ET &	PD ANY	<u>ki kir</u>	\$` :
		T		

Den like		
A)	A14	KOCHEL et al., Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products, Virology, 182:644-54, 1991
	A15	HARLAN et al., Cervical cancer screening: who is not screened and why?, American Journal of Public Health, 81:885-91, 1991
	A16	SCHIFFMAN MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute, 84:394-8, 1992
	A17	LORINCZ et al., Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types, Obstetrics and Gynecology, 79:328-37, 1992
	A18	JOCHMUS et al., Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies, Molecular and Cellular Problems, 6:319-25, 1992
	A19	SLAWSON et al., Follow up papanicolau smear for cervical atypia: Are we missing significant disease?, Journal of Family practice, 36(3):289-93, 1993
	A20	PARK et al., Human papillomavirus type 16 E6, E7, and L1 and type 18 E7 proteins produced by recombinant baculoviruses, Journal of Virological Methods, 45:303-318, 307, 1993
	A21	HAMSIKOVA et al., Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls, Journal of Infectious Disease, 170:1424-31, 1994
	A22	HUTCHINSON et al., Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor, American Journal of Clinical Pathology, 101:215-33, 1994
	A23	FU et al., Diagnosis between condyloma acuminatum and pseudocondyloma in lower female genital tract as determined by a PCR-based method, Chinese Journal of Obstetrics and Gynecology, 29:168-88, 1994
	A24	FU et al., Human papillomavirus and papillomatosis lesion of female lower genital tract, Infectious Disease Obstetrics and Gynecology, 10:235-41, 1994
	A25	MULLER et al., Antibodies to the E4, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated disease and in the normal population, Journal of Investigative Dermatology, 104:138-41, 1995
	A26	GREGOIRE et al., Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma, Journal of the National Cancer Institute, 87(22):1705-9, 1995
	A27	CHEE et al., Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins, Gynecology Oncology, 57:226-231, 1995
	A28	COX et al., Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, American Journal of Obstetrics and Gynecology, 172:946-64, 1995
	A29	FERENCY et al., Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, American Journal of Obstetrics and Gynecology, 1775:651-6, 1996
	A30	DONNELLY et al., Protection against papillomavirus with a polynucleotide vaccine, Journal of Infectious Disease, 713:314-20, 1996

EXAMINER	DATE CONSIDERED 4/25/05

ESTER A)	A31	BORYSLEWICZ et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer, Lancet, 347:1523-7, 1996
	A32	BIRDSONG C.G., Automated rescreening of Pap smears: what are the implications?, Diagnostic Cytopathology, 13:283-8, 1996
	A33	SOINI et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax, 51:887-93, 1996
	A34	ANONYMOUS, Cervical cancer, NIH Consensus Statement Apr 1-3; 14(1):1-38, 1996
	A35	KONYA et al., Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein, Journal of General Virology, 78:2615-20, 1997
	A36	VERDON ME, Issues in the management of human papillomavirus genital disease, American Family Physician, 55:1813-16, 1997
	A37	BRYAN et al., Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle, Journal of Med Virology, 53:185-8, 1997
	A38	SUGASE et al., Distinct manifestations of human papillomaviruses in the vagina, International Journal of Cancer, 72: 412-5, 1997
	A39	CLAVEL et al., DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR, Journal of Clinical Pathology, 51(1):38-43, 1998
	A40	LOWY et al., Papillomaviruses: prophylactic vaccine prospects, Biochimistre et Biophysica Acta, 1423(1):M1-8, 1998
	A41	ARENDS et al., Aetiology, pathogenesis, and pathology of cervical neoplasia, Journal of Clinical Pathology, 51:96-103, 1998
	A42	MESCHEDE et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, Journal of Clinical Microbiology, 36(2):475-80, 1998
	A43	RICE et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology, 9:15-21, 1999
	A44	WALBOOMERS et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology, 189:12-19, 1999
	A45	SUN et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology Biomarkers & Prevention, 8(10):935-40, 1999
	A46	NOBBENHUIS et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, Lancet, 354:20-5; 1999
	A47	SILINS et al, Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology, 80: 2931-6, 1999

EXAMINER	DATE CONSIDERED	4/25/05

A48

HAGENSEE et al., Seroprevalence of human papillomavirus type 16 in pregnant women, Obstetrics and Gynecology, 94:653-8, 1999

As	A49	CUZICK et al., A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions, British Journal of Cancer, 83(5):561-5, 2000	
	A50	PIROG et al., Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, American Journal of Pathology, 157:1055-62, 2000	
	A51	FRISCH et al., Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S., Cancer, 88(6):1464-9, 2000	
	A52	MELLIN et al., Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival, International Journal of Cancer (Pred. Oncol.), 89:300-4, 2000	
	A53	ZUMBACH et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma, International Journal of Cancer, 85:815-8, 2000	
	A54	WRIGHT et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association, 283:81-6, 2000	
	A55	DREAU et al., Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression, Annals of Surgery, 231(5):664-71, 2000	
	A56	PETTER et al., Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women, Journal of General Virology, 81:701-8, 2000	

EXAMINER	DATE CONSIDERED	4/25/05
----------	-----------------	---------